Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples